The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...
Medscape Business of Medicine, August 14, 2015 PVCs: Modifiable Risk Factor for Heart Failure . . . Maybe ... adherent adopter of the new ARNI heart failure drug. theheart.org on Medscape, August ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback